<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013041212958N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-06-07</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ultra-low  dose of naloxone on analgesia after abdominal wall nerves block in patients after cesarean section</public_title>
      <acronym>-</acronym>
      <scientific_title>The opioid sparing  effect of adding ultra-low doses of naloxone  to bupivacaine% 0/25 with or without sufentanil in Transverse Abdominis Plane Block on patients after elective caesarean section  ;double- blind, randomized , clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-01-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>164</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/12939</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>pain.</hc_freetext>
      <i_freetext>Intervention 1: under guidence of ultrasonography Transverse abdominis Block performed bilateraly in    control group "patients recieved 18 ml bupivacaine 0.25% along with 2 cc normal saline on each sideIn the recovery room, pain intensity was measured at baseline then  2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded . Intervention 2: under guidence of ultrasonography Transverse abdominis Block performed bilateraly in sufentanil group patients recieved 18 ml bupivacaine 0.25% along with 1 cc normal saline and 1 ml sufentanil (5 microgram) on each sideIn the recovery room, pain intensity was measured at baseline then 2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded. Intervention 3: under guidence of ultrasonography Transverse abdominis Block performed bilateraly in naloxone and sufentanil group patients recieved 18 ml bupivacaine 0.25% along with 1 cc naloxone (100 nanogram)  alon with 5 microgram sufentanil on each side In the recovery room, pain intensity was measured at baseline then 2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded. Intervention 4: under guidence of ultrasonography Transverse abdominis Block performed bilateraly in Naloxone  group patients recieved 18 ml bupivacaine 0.25% along with 1 cc normal saline alon with 100 nanogram (1 ml) Naloxone on each side In the recovery room, pain intensity was measured at baseline then 2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Samira Sorbi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr.Ali Shariati Hospital, North Karegar St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>-</zip>
        <telephone>+98 21 8490 2373</telephone>
        <email>khatere80@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Movafegh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr.Ali Shariati, North Karegar St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>-</zip>
        <telephone>+98 21 8490 2397</telephone>
        <email>movafegh@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>inclusion criteria:&#13;
age 20-40; ASA class I,II; primigravid; non addict; without history of allergy to protocol drugs&#13;
Excluxion criteria:&#13;
patients whom recieved drugs other than the ones mentioned in protocol in 24 h preoperation; surgery duration more than 90 minutes</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>acute pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>under guidence of ultrasonography Transverse abdominis Block performed bilateraly in    control group "patients recieved 18 ml bupivacaine 0.25% along with 2 cc normal saline on each sideIn the recovery room, pain intensity was measured at baseline then  2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded .</i_keyword>
      <i_keyword>under guidence of ultrasonography Transverse abdominis Block performed bilateraly in sufentanil group patients recieved 18 ml bupivacaine 0.25% along with 1 cc normal saline and 1 ml sufentanil (5 microgram) on each sideIn the recovery room, pain intensity was measured at baseline then 2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded</i_keyword>
      <i_keyword>under guidence of ultrasonography Transverse abdominis Block performed bilateraly in naloxone and sufentanil group patients recieved 18 ml bupivacaine 0.25% along with 1 cc naloxone (100 nanogram)  alon with 5 microgram sufentanil on each side In the recovery room, pain intensity was measured at baseline then 2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded</i_keyword>
      <i_keyword>under guidence of ultrasonography Transverse abdominis Block performed bilateraly in Naloxone  group patients recieved 18 ml bupivacaine 0.25% along with 1 cc normal saline alon with 100 nanogram (1 ml) Naloxone on each side In the recovery room, pain intensity was measured at baseline then 2h, 6h, 12h, 24h postoperatively using visual analoge scale and the time of first request for analgesic and opioid consumption during 24 h postoperation also wrer recorded</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intesity. Timepoint: recovery room,2,6,12,24 h after surgery. Method of measurement: visual analoge scale.</prim_outcome>
      <prim_outcome>Morphine consumption. Timepoint: recovery room, 2,6,12,24h after surgery. Method of measurement: opioid registration by milligram.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sensory Block Duration. Timepoint: 24h. Method of measurement: Pinprick test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-09-26</approval_date>
        <contact_name>Ethics Committee, Faculty of Medicine</contact_name>
        <contact_address>Faculty of Medicine, Tehran University of Medical Sciences and Health Care Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
